Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report
Immune checkpoint inhibitors (ICIs) have had a revolutionary effect on the treatment of patients with advanced non-small cell lung cancer (NSCLC), especially squamous cell lung cancer. However, ICIs may cause associated immune-related adverse events (ir-AEs). No case of sintilimab-induced toxic epid...
Main Authors: | Gang Li, Sheng Gong, Ning Wang, Xiaojun Yao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.989966/full |
Similar Items
-
Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma
by: Huayu Yang, et al.
Published: (2022-12-01) -
Toxic Epidermal Necrolysis
by: Syed Naveed Ali Shah, et al.
Published: (2020-11-01) -
Important Points in Toxic Epidermal Necrolysis Management
by: Sultan
Published: (2019-07-01) -
Simvastatin-induced Toxic Epidermal Necrolysis
by: Emmanouil Petrou, et al.
Published: (2014-01-01) -
A case of toxic epidermal necrolysis probably due to etoricoxib
by: Sayanta Thakur, et al.
Published: (2019-01-01)